Is quetiapine (Seroquel) safe to use during pregnancy?

Quetiapine (Seroquel) Use During Pregnancy

Quetiapine can be used during pregnancy when clinically necessary, as it carries a relatively low risk of major congenital malformations compared to other antipsychotics, though it may be associated with modest increases in certain pregnancy complications.

Risk of Major Congenital Malformations

• Quetiapine shows a small but statistically significant increase in overall major malformations (OR 1.19; 95% CI 1.01-1.39) compared to unexposed pregnancies, but this represents one of the lowest teratogenic risks among antipsychotics 1.

• The absolute risk of major malformations remains very low at approximately 1.3-2.2%, which is comparable to baseline population rates 2, 3.

• No specific pattern of malformations has been identified with quetiapine exposure, and prospective registry data show reassuring safety profiles with confidence intervals not exceeding a fivefold increased risk 3.

• Quetiapine appears safer than risperidone (OR 1.43), olanzapine (OR 1.33), aripiprazole (OR 1.30), and lithium (OR 1.61) for congenital malformations 1.

Obstetric and Neonatal Complications

Gestational Diabetes Mellitus:

• Quetiapine is more frequently associated with gestational diabetes compared to other antipsychotics (ROR 0.22 for other antipsychotics vs. quetiapine as reference) 4.
• Women using any antipsychotic have increased risk of gestational diabetes (aOR 1.64; 95% CI 1.19-2.27) 5.

Postpartum Hemorrhage:

• Increased risk of postpartum bleeding in vaginal delivery (aOR 1.65; 95% CI 1.13-2.42) has been documented with quetiapine use 5.

Neonatal Outcomes:

• Prolonged neonatal hospitalization (≥5 days) occurs more frequently (aOR 1.54; 95% CI 1.10-2.15) 5.
• The FDA label warns that neonates may experience extrapyramidal and/or withdrawal symptoms including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding disorder 6.
• Higher placental-to-birth-weight ratio has been observed (aB 0.009; 95% CI 0.002-0.016) 5.

Spontaneous Abortion:

• No definitive increased risk has been established, and any association likely reflects confounding by underlying psychiatric illness rather than medication effect 4.

Clinical Decision-Making Algorithm

When to Continue Quetiapine:

• Severe psychiatric symptoms requiring antipsychotic treatment
• History of decompensation after medication discontinuation
• Failed trials of non-pharmacologic interventions
• Risk of harm to mother or fetus from untreated illness outweighs medication risks 7

When to Consider Alternatives:

• If gestational diabetes is a major concern, consider lamotrigine (for bipolar disorder) or haloperidol, which show lower reporting frequencies for this outcome 1, 4
• For patients requiring antipsychotic therapy with lower malformation risk, ziprasidone and paliperidone show similar or lower reporting frequencies compared to quetiapine, though data are more limited 4

Monitoring Requirements During Pregnancy

Maternal Monitoring:

• Glucose screening at baseline and throughout pregnancy given elevated gestational diabetes risk 5
• Blood pressure monitoring at each prenatal visit 6
• Weight gain assessment at each visit, as quetiapine causes weight gain 6
• Lipid profile at baseline and periodically during treatment 6

Fetal Monitoring:

• Standard anatomic ultrasound at 18-22 weeks (no specific cardiac screening required as with bupropion) 3
• Fetal growth monitoring given association with altered placental-to-birth-weight ratio 5

Neonatal Monitoring:

• Observation for withdrawal symptoms and extrapyramidal signs in the first 48-72 hours after delivery 6
• Respiratory status and feeding assessment 6
• Plan for potential prolonged hospitalization if symptoms develop 5

Important Caveats and Pitfalls

Confounding by Indication:

• Much of the observed risk may reflect underlying psychiatric illness rather than medication exposure itself 8, 4.
• Women with psychiatric disorders requiring antipsychotics often have multiple risk factors including smoking, substance use, obesity, and use of other psychotropic medications 5.

Avoid Abrupt Discontinuation:

• Do not stop quetiapine abruptly without weighing maternal risks, as untreated psychosis can jeopardize both maternal and fetal health 7.
• If discontinuation is attempted, it should be gradual and only when psychiatric stability allows 7.

Pregnancy Registry:

• Advise patients about the National Pregnancy Registry for Psychiatric Medications (NCT01246765), which continues to collect safety data 6, 2.

Comparative Context:

• While quetiapine shows some increased risks, it remains among the safer antipsychotic options during pregnancy when compared head-to-head with other agents 1, 4.
• The magnitude of documented risks is not clinically prohibitive when balanced against the risks of untreated psychiatric illness 7.